Yeomyeong Kim
Seoul, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
CU06-1004 inhibits the progression of chronic colitis and colitis-associated colorectal cancer by suppressing inflammation.
Journal: Frontiers in pharmacology
Published: August 13, 2025
CU06-1004 alleviates oxidative stress and inflammation on folic acid-induced acute kidney injury in mice.
Journal: Journal of pharmacological sciences
Published: October 30, 2023
A novel small molecule, CU05-1189, targeting the pleckstrin homology domain of PDK1 suppresses VEGF-mediated angiogenesis and tumor growth by blocking the Akt signaling pathway.
Journal: Frontiers in pharmacology
Published: August 10, 2023
Efficacy of CU06-1004 via regulation of inflammation and endothelial permeability in LPS-induced acute lung injury.
Journal: Journal of inflammation (London, England)
Published: December 01, 2022
Oral administration of CU06-1004 attenuates vascular permeability and stabilizes neovascularization in retinal vascular diseases.
Journal: European journal of pharmacology
Published: July 14, 2022
CU06-1004 enhances vascular integrity and improves cardiac remodeling by suppressing edema and inflammation in myocardial ischemia-reperfusion injury.
Journal: Experimental & molecular medicine
Published: July 08, 2021
MicroRNA-148a/b-3p regulates angiogenesis by targeting neuropilin-1 in endothelial cells.
Journal: Experimental & molecular medicine
Published: May 13, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026